. Earth Science News .
EPIDEMICS
Chinese coronavirus jab brings relief, and concern in Hungary
By Peter MURPHY
Budapest (AFP) Feb 26, 2021

China approves two more domestic coronavirus vaccines
Beijing (AFP) Feb 25, 2021 - China's drug authority said Thursday it had approved two more coronavirus vaccines made by domestic companies for public use.

The vaccines made by CanSino Biologics and a unit of Sinopharm were given conditional approvals after they were found protective against Covid-19, said the National Medical Products Administration.

Conditional approvals help to speed emergency drugs to market in cases when clinical trials are yet to meet normal standards but indicate therapies will work.

Sinopharm affiliate Wuhan Institute Of Biological Products says its vaccine has an efficacy rate of 72.51 percent, while the overall efficacy for CanSino's stands at 65.28 percent after 28 days.

China has now approved four domestic vaccines, after approving Sinovac's CoronaVac jab earlier this month, and another Sinopharm product in December.

On Thursday, the Chinese drug agency said it would require both licence holders to "continue carrying out relevant research, complete the conditional requirements, and submit follow-up research results in a timely manner".

But the published efficacy rates of China's vaccines remain behind rival jabs by Pfizer-BioNTech and Moderna, which have 95 percent and 94 percent rates respectively.

China has been rushing to develop homegrown jabs, and set a goal to vaccinate 50 million people by mid-February. As of February 9, more than 40 million doses had been administered.

The country is also providing free vaccines to 53 countries, and exporting to more than 20 others who have made purchasing requests.

"We should be happy to get any vaccine," said Laszlo Cservak, a pensioner queueing in Budapest for China's Sinopharm Covid-19 vaccine shot after Hungary became the first EU member to start using it.

The inoculations began Thursday as some Hungarian doctors fret that Sinopharm's Chinese maker has provided only minimal information on clinical trials of its vaccine, particularly for those aged over 60.

Neither Sinopharm nor Russia's Sputnik V jab, which Budapest also started rolling out this month in another EU first, are approved by the EU's European Medicines Agency (EMA).

In surveys of preferences among the five vaccines now used in Hungary, Sinopharm ranks last behind three western-developed vaccines -- Pfizer-BioNTech, Moderna and AstraZeneca -- as well as Sputnik V.

Prime Minister Viktor Orban and health officials have urged citizens to put aside concerns about the Chinese vaccine while pro-government media have promoted its benefits.

For Cservak, waiting restlessly to be called into a vaccination centre -- a pensioners club near the river Danube -- scepticism about the Chinese drug is unwarranted.

"We are a country of 10 million virus experts, and some media are guilty of raising doubts in people who then hesitate to choose non-western vaccines," the 75-year-old told AFP.

- "Can't wait" -

The first batch of 550,000 Sinopharm jabs from China arrived earlier this month accompanied by fanfare in public media.

Hungary expects to get a further one million doses in March and April in total, with 3.5 million more doses arriving in May, a senior minister said Thursday.

Some 50-55 doses each have already been dispatched to family doctors, who have been tasked with arranging appointments with patients on their roster.

"About 70 percent of the 67 patients on my list accepted to come in for a shot," Dr. Emese Bone told AFP while staff helped arriving patients to fill out forms.

"But several elderly heard that there is not enough data on its effects on their age group, and while they think anything is better than getting Covid they decided to wait," said Bone.

"A few worried about the lack of EMA approval, while three changed their mind about coming after hearing they might not be able to travel in Europe if they get non-EU jabs," she said.

According to Szilvi Eszes, a nurse administering the jabs, those in the queue unsurprisingly had few reservations about the Chinese vaccines as they had already registered on a government vaccination website signed so far by around 2.5 million people.

"They might prefer Pfizer or Moderna but this is what is here now, they are free to say no, although who knows what will be available later and when," she told AFP.

After receiving her shot Ilona Mester, 59, said she "can hardly wait" for the second dose in a month's time.

"When they told me yesterday it would be the Chinese vaccine I wasn't worried, I had read good things about it, and only had to think for a bit before accepting the appointment, I would have taken any vaccine, to be honest," she said.

- Inoculation drive -

So far, almost half a million Hungarians have received at least one vaccine dose, mostly Pfizer shots, but officials said Thursday that the pace of inoculations will double with the newly procured Chinese jabs.

All those who have registered on the government's website can be vaccinated by early April, said the country's chief surgeon.

The inoculation drive comes as an extension of a partial lockdown in place since November until March 15 was announced Thursday following a steep rise in new infection cases.

"Without the Chinese and Russian vaccines we would be in big trouble," Orban said Friday in an interview, while criticising the "slow" pace of deliveries from the EU.

"Hungary can be the most vaccinated country in Europe by Easter," he said, pledging to receive his own Sinopharm jab next week.

Critics have accused the 57-year-old premier of pressuring health authorities to green-light non-EU vaccines to win favour from China and Russia.

A government decree last month drastically loosened approval criteria of vaccines worldwide.

A leading doctors association said it could not recommend the Chinese or Russian drugs to colleagues "in good conscience" due to inadequate documentation.

But among those leaving the vaccination centre relief was the main emotion.

"A year ago I felt myself a young man, now I am an old man, I horribly miss not going to the pool or gym, and travelling, so I came here to get liberated and my old life back," said Laszlo Cservak.


Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola


Thanks for being here;
We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor
$5 Billed Once


credit card or paypal
SpaceDaily Monthly Supporter
$5 Billed Monthly


paypal only


EPIDEMICS
Privacy faces risks in tech-infused post-Covid workplace
Washington (AFP) Feb 21, 2021
People returning to work following the long pandemic will find an array of tech-infused gadgetry to improve workplace safety but which could pose risks for long-term personal and medical privacy. Temperature checks, distance monitors, digital "passports," wellness surveys and robotic cleaning and disinfection systems are being deployed in many workplaces seeking to reopen. Tech giants and startups are offering solutions which include computer vision detection of vital signs to wearables which ca ... read more

Comment using your Disqus, Facebook, Google or Twitter login.



Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle

EPIDEMICS
In gritty Paris suburb, virus sparks 'social tsunami'

Greek govt under fire as power outages persist

Senator's Mexico trip draws ire as Texas hit by winter storm

Quake-hit Christchurch regains its mojo, 10 years on

EPIDEMICS
Concept for a new storage medium

Aerosol pollution caused decades of "global dimming"

Falling to Earth takes a long time

More sustainable recycling of plastics

EPIDEMICS
Tool that more efficiently analyzes ocean color data will become part of NASA program

US stops Trump's aid freeze to Ethiopia over dam dispute

Texans queue for water as US counts cost of deadly winter storm

Coral reef predators get 70% of their energy from the open ocean

EPIDEMICS
Effects of past ice ages more widespread than previously thought

Ancient relic points to a turning point in Earth's history 42,000 years ago

India's glacier disaster highlights Himalayan dangers

U.S., 4 partner nations sign letter of intent for Arctic Challenge Exercise

EPIDEMICS
Reed harvest in snowy Poland

Three technologies poised to change food and the planet

Corn belt farmland has lost a third of its carbon-rich soil

Kenya's locust hunters on tireless quest to halt ancient pest

EPIDEMICS
Quake rocks Reykjavik, raises Iceland's volcano activity

Severe floods kill five in Indonesia's capital

Indonesia volcano erupts, spews red-hot lava

Quake injures more than 30 in southwest Iran

EPIDEMICS
As peace deal drifts, South Sudan risks fresh crisis

Jihadists overrun Nigerian army base; Plane crash in kidnap rescue op

Tanzanian bow-and-arrow hunters offer insight on evolution of technology

Five things to know about Niger

EPIDEMICS
Outsider threats inspire bonding, cooperation among chimpanzees

For more equitable cities, researchers say to keep social networks intact

CT scans of Egyptian mummy suggest 'brave' pharaoh was executed

Some of our gut microbiota predates the human-Neanderthal split









The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.